Drug Trial Radar · NCT03162536
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
190
Planned (sponsor's estimate)
Start
Jun 26, 2017
Primary completion
Sep 17, 2027
Study completion Sep 17, 2027
Sponsor
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Industry
- Sponsor type
- Industry
- First posted
- May 22, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies. No formal hypothesis testing will be performed for this study.
Conditions
- Lymphoma, B-Cell
- Small Lymphocytic Lymphoma
- Chronic Lymphocytic Leukemia
- Waldenstrom Macroglobulinemia
- Mantle Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Richter's Transformation
- Follicular Lymphoma
- Marginal Zone Lymphoma
Interventions
NemtabrutinibDrug
Nemtabrutinib will be orally administered once per day under fasted conditions (1 hour prior to or 2 hours after a meal) and is available in tablets in strengths of 5 mg or 20 mg. For Expansion Food Effect Cohort I, nemtabrutinib will be orally administered once per day under fasted and non-fasted condition.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants Experiencing Dose Limiting Toxicity (DLT)Time frame: Cycle 1 (up to 28 days)
- Phase 1: Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 86 months
- Phase 1: Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to approximately 86 months
- Phase 2: Expansion Cohorts A, B & C: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria as Assessed by the InvestigatorTime frame: Up to approximately 64 months
- Phase 2: Expansion Cohorts A, B, C: ORR per Lugano Classification as Assessed by the InvestigatorTime frame: Up to approximately 64 months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Hospital ( Site 0140)
Scottsdale, Arizona
UCLA Hematology & Oncology ( Site 0017)
Los Angeles, California
Colorado Blood Cancer Institute ( Site 0225)
Denver, Colorado
University of Michigan ( Site 0018)
Ann Arbor, Michigan
Mayo Clinic - Rochester ( Site 0138)
Rochester, Minnesota
Duke Cancer Center ( Site 0067)
Durham, North Carolina
The Ohio State University Wexner Medical Center ( Site 0056)
Columbus, Ohio
Tennessee Oncology, PLLC ( Site 0020)
Nashville, Tennessee
UT Southwestern Medical Center ( Site 0116)
Dallas, Texas
University of Utah, Huntsman Cancer Institute ( Site 0122)
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.